bioserve
Currently not logged in:
Available Tumor and Normal Adjacent Pairs
Breast Cancer
Ovarian Cancer
Colon Cancer
Lung Cancer
GI Cancer
Available Patient Data
Age
Gender
Ethnicity
Diagnosis
Pathology
Treatment

High Quality Total RNA Isolated from Fresh Frozen Human Tissue

BioServe's OncoRNA are derived from fresh frozen, fully annotated high quality tumors and adjacent normal tissues from BioServe's Global Repository. BioServe has initially focused on colon, lung, breast, ovarian, and GI cancers but plans to expand the product line into other tumors. These samples are ideally suited for miRNA profiling, gene expression, RT-PCR, array analysis, Northern analysis, RPA and cDNA library construction. This clinical biomaterial is delivered with comprehensive demographic and clinical information, including family history, diagnostic, and treatment data.

Cancer Tissue and RNA Handling

Today's sophisticated analysis techniques require the highest quality total RNA. BioServe has nearly 20 years experience processing and storing nucleic acids. Over the years, BioServe has developed and validated hundreds of protocols for the isolation of high quality nucleic acid from various starting material.

Source Tissue Details:

  • Surgically obtained by board certified surgeons
  • Snap frozen within 45 minutes of arterial ligation in the operating room
  • Tissue kept in liquid nitrogen vapor freezers until RNA isolation

RNA Isolation Procedure:

  • Trizol total RNA isolation to maintain micro RNA population
  • Single tissue RNA, not pooled from several donors
  • OD and Agilent Bioanalyzer quality control of integrity and stability
  • Stored in 5ug aliquots at liquid nitrogen vapor freezers
Using the high quality RNA samples from BioServe, we were able to identify novel microRNA sequences that could potentially be involved in the generation of new tumor tissues, particularly in colorectal cancer...If more stringently validated, these disease-related miRNAs may eventually serve as targets for diagnostic or therapeutic development.

Chris Adams, Research Area Manager

Epigenetics at Invitrogen